Clinical Trials Logo

Aortic Valve Regurgitation clinical trials

View clinical trials related to Aortic Valve Regurgitation.

Filter by:

NCT ID: NCT06455787 Not yet recruiting - Clinical trials for Aortic Valve Regurgitation

J-Valve Transfemoral Pivotal Study

JOURNEY
Start date: July 2024
Phase: N/A
Study type: Interventional

The primary objective of this study is to assess the safety and efficacy of the J-Valve Transfemoral (TF) System in patients with symptomatic, severe (grade 3 or 4), native aortic valve regurgitation (AR) and AR-dominant mixed aortic valve disease, who are judged by a multi-disciplinary heart team to be at high risk for open surgical aortic valve replacement (SAVR).

NCT ID: NCT06381271 Recruiting - Clinical trials for Aortic Valve Regurgitation

Transcatheter Aortic Valve Replacement for Pure Severe Aortic Valve Regurgitation

Start date: October 30, 2018
Phase:
Study type: Observational

The purpose of this multicenter, prospective and observational registry is to evaluate the safety and efficacy of TAVR for treatment of pure severe aortic valve regurgitation. Baseline characteristics, procedural and clinical data will be collected

NCT ID: NCT05902897 Recruiting - Clinical trials for Aortic Valve Stenosis

Aortic or Mitral Valve Replacement With the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis

Start date: January 1, 2023
Phase:
Study type: Observational

Collect data on the safety and clinical performance of the Braile Biomédica® Bovine Pericardium Valvular Bioprosthesis

NCT ID: NCT05799573 Recruiting - Clinical trials for Aortic Valve Regurgitation

CT Scan Sizing for Perceval Sutureless Valve

PERCEVAL
Start date: December 1, 2022
Phase:
Study type: Observational

The Perceval sutureless aortic bioprosthesis is a bovine pericardium valve mounted in a nitinol stent that can be compressed and positioned in a valve delivery system. Similarly, to transcatheter aortic valve implantation (TAVI) devices, the anchoring and good sealing of the Perceval bioprosthesis relies on oversizing by design of the nitinol stent compared with the native aortic annulus. With the advent of TAVI, cardiac computed tomography (CT) has become the gold standard technique for measuring the aortic annulus in patients undergoing transcatheter procedures, and the CT-derived axial image of the aortic virtual basal ring (VBR) is considered as the reference for sizing by most of the manufacturers of transcatheter valves . Interestingly, the VBR lies exactly on the plane passing through the nadir of the 3 aortic cusps, that is where, according to the instructions for use, a correctly positioned Perceval valve should be deployed. VBR could then provide a good estimate of the annular dimension for the Perceval pre-operative sizing.

NCT ID: NCT05536310 Not yet recruiting - Clinical trials for Aortic Valve Stenosis

TAVIS Registry - Trilogy Heart Valve System for Management of Patients With Aortic Valve Disease

TAVIS
Start date: March 2023
Phase:
Study type: Observational [Patient Registry]

To collect information about the management of symptomatic severe Aortic Stenosis (AS) and Aortic Regurgitation (AR) using transcatheter aortic valve replacement (TAVI).

NCT ID: NCT05459233 Recruiting - Clinical trials for Aortic Valve Stenosis

Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR

ECHOCATH
Start date: January 11, 2023
Phase: N/A
Study type: Interventional

Data on valve performance following ViV-TAVR has usually been obtained with the use of Doppler-echocardiography. However, some reports have shown significant discordances in the evaluation of mean transvalvular gradient between echocardiography and catheterization, with an overestimation of the real gradient with echo (vs. cath) in most cases. Thus, the incidence of procedural-device failure may be lower than that reported in the ViV-TAVR literature,

NCT ID: NCT05438862 Recruiting - Clinical trials for Aortic Valve Regurgitation

Early Aortic vaLve surgEry Versus wAtchful waitiNg Strategy in Severe Asymptomatic aOrtic reguRgitation

ELEANOR
Start date: September 1, 2022
Phase: N/A
Study type: Interventional

The optimal timing of surgical intervention in asymptomatic patients with severe aortic regurgitation remains controversial. As per cardiac magnetic resonance assessment, early surgical treatment will be compared with conventional guideline-based strategy in asymptomatic patients with severe aortic regurgitation.

NCT ID: NCT04797572 Recruiting - Clinical trials for Aortic Valve Regurgitation

Clinical Evaluation of the Free Margin Cusp Sizer (CALIBRATE)

CALIBRATE
Start date: March 22, 2021
Phase: N/A
Study type: Interventional

The objective of this study is to investigate safety and performance of the Free Margin Cusp sizer. The device will be used during aortic valve repair and sparing procedures as a caliper to measure the aortic valve free margin length at different stages of the procedure. The patient will be followed for one year clinically (at 1, 2, 6 and 12 months) and by echocardiography (at 6 and 12 months) to assess aortic valve function.

NCT ID: NCT04548726 Completed - Clinical trials for Aortic Valve Stenosis

Hemodynamic Matched Comparison of the Balloon-Expandable Transcatheter Heart Valves Myval and Sapien-3 for the Treatment of Aortic Stenosis

MATCH-BALL
Start date: June 1, 2018
Phase:
Study type: Observational

Transcatheter aortic valve implantation (TAVI) is recommended for patients with severe aortic stenosis (AS) at high to intermediate surgical risk. Despite similar mortality rates compared to surgical aortic valve replacement (SAVR) in this setting, the rate para-valvular leak (PVL) remains higher and has been associated to higher mortality even at mild degree. This is one of the major concerns to extend TAVI to low surgical risk, although the favorable results from PARTNER 3. The presence of moderate to severe PVL after TAVI is associated to a 2- and 3- fold increase in the mortality rate at 30-day and 1-year follow-up, respectively (24-29). Prosthesis-patient mismatch (PPM) adversely affects functional improvement and exercise tolerance, left ventricular (LV) mass regression, and late structural valve deterioration. Many studies have previously investigated PPM after surgical AVR suggesting the presence of this problem in more than 40% of the surgically treated patients. This rate was significantly lower with the balloon-expandable Sapien (Edwards Lifesciences, Irvine, California), with PPM that varied from 8% to 18%, but in both cases (patients harboring TAVI and those with SAVR) the mortality rate was higher in the presence of PPM. Under the hypothesis that there are differences in terms of transvalvular gradients and residual para-valvular leak amongst different balloon-expandable TAVI devices available in the market, the aim of the MATCH-BALL study is to compare the hemodynamic performance of two balloon-expandable TAVI devices, Sapien 3 (Edwards Lifesciences, Irvine, CA, USA) and Myval (Meril Life Sciences Pvt. Ltd., India).

NCT ID: NCT04464655 Recruiting - Clinical trials for Coronary Artery Disease

A 10-Minute Cardiovascular Magnetic Resonance Protocol for Cardiac Disease

Start date: December 12, 2019
Phase:
Study type: Observational

This study aims to identify and assess new CMR techniques that can improve current CMR protocols.